PEN and BSX Related Headlines
Go Back- Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
- Boston Scientific announces results for fourth quarter and full year 2025
- Mizuho on Boston Scientific (BSX): 'we do not foresee any FTC risk concerns'
- Jefferies Downgrades Penumbra (PEN) to Hold
- Wells Fargo Downgrades Penumbra (PEN) to Equal Weight
- Morgan Stanley on Boston Scientific (BSX): 'Stock is looking too cheap and has clear catalysts'
- William Blair Downgrades Penumbra (PEN) to Market Perform
- Penumbra surges on news of $14.5 billion Boston Scientific buyout, BSX down
- Boston Scientific to acquire Penumbra for $14.5 billion
- Boston Scientific announces agreement to acquire Penumbra, Inc.
- BofA’s six MedTech picks for 2026 on strong earnings growth
PEN and BSX Related Press Releases
Go Back- Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
- Boston Scientific announces results for fourth quarter and full year 2025
- Boston Scientific announces agreement to acquire Penumbra, Inc.
